Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells

Human Antibodies

Volumn 7, Issue 1, 1996, Pages 2-10

  Xiang, Jim ^a   Qi, Yumin ^a   Cook, Dan ^a   Moyana, Terence ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Anti TAG72 antibody; Fusion protein; IFN

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HYBRID PROTEIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PURIFICATION; TARGET CELL; TUMOR CELL;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CLONING, MOLECULAR; COLONIC NEOPLASMS; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029908874     PISSN: 10932607     EISSN: 1875869X     Source Type: Journal    
DOI: 10.3233/HAB-1996-7101     Document Type: Article

References (48)

1. Gray P. Leung D, Pennica D, Yelverton E, Najarian R, Simonsen C, Derynk R, Sherwood P, Wallace D, Berger S, Levinson Rand Goeddel D.Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 1982; 295: 503
2. Yong HA, Hardy K. Interferon-T: Producer cells, activation, stimuli, and molecular genetic regulation. Pharm Ther 1990; 45: 137
3. Ros F, Cochet M, Fellous M. Interferon and major histocompatibility complex genes: A model to analyze eukaryotic gene regulation. In: Gresser. I, ed. Interferon-T, London: Academic Press Inc. 1986
4. Schwartz R, Momburg F, Moldenhauer G, Dorken B, Schirrmacher V. Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-T. Int J Cancer 1985; 35: 245
5. Tanaka K, Isselbacher K, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985; 228: 26
6. Giacomini P, Fraioli R, Nistico P, Tecce R, Nicotra M, Di Filippo F, Fisher P, Nitali P. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple antologous metastases by recombinant human leukocyte fibroblast, and immune interferon. Int J Cancer 1990; 46: 539
7. Greiner J, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher P, Schlom J. Recombinant interferon enhances monoclonal antibodytargeting of carcinoma lesions in vivo. Science 1987; 235: 895
8. Kantor J, Tran R, Greiner J, Pestka S, Fisher P, Shively J, Schlom J. Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human T-interferon. Cancer Res 1989; 49: 2651
9. Rowlinson G, Balkwill F, Snook D, Hooker G and Epenetos A. Enhancement by T-interferon of in vivo tumor radio-localization by monoclonal antibody against HLA-DR antigen. Cancer Res 1986; 46: 6413
10. Gansbacher B, Banner R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated T-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res 1990; 50: 7820
11. Palladino M, Shalaby M, Kramer S, Baughman R, Deleo A, Crase D, Marafino B, Aggarwal B, Patton J. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol 1987; 138: 4023
12. Haq A, Rinehart J, Maca R. The effect of gamma interferon on IL-I secretion of in vitro differentiated human macrophages. J Leukocyte Bioi 1985; 38: 735
13. Fady C, Gardner A, Gera J, Lichtenstein A. Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by Iymphokine-activated killer cells: Selective effects on HER2/neu expressing cells. Cancer Res 1992; 52: 764
14. Tsujimoto M, Yip Y, Vilcek J. Interferon-τ enhances expression of cellular receptors for tumor necrosis factor. J Immunol 1986; 136: 2441
15. We lander C, Homesley H, Reich S, Levin E. A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 1988; 11: 465
16. Malik S, Knowles R, East N, Lando D, Stamp G, Balkwill F. Antitumor activity of T-interferon in ascites and solid tumor models of human ovarian cancer. Cancer Res 1991; 51: 6643
17. ErnstoffM, Gooding W, Nair S, Bahnson R, Mikketic L, Banner B, Day R, Whiteside T, Kirkwood J. Immunological effects of treatment with sequential administration of recombinant interferon-τ and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res 1992; 52: 851
18. Ponzoni M, Casalaro A, Lanciotti M, Montaldo P, Cornaglia-Ferraris P. The combination of τ-interferon and tumor necrosis factor causes a rapid and extensive differentiation of human neuroblastoma cells. Cancer Res 1992; 52: 931
19. Bocci V, Carraro F, Naldini A, Borrelli E, Giagi G, Gotti G, Giomarelli P. Interferon levels in human pulmonary tumors are lower than plasma levels. J Biol Reg Homeostant Agents 1990; 4: 153
20. Bocci V, Carrarp F, Naldini A, Cagol P, Pasqual E, Prevaldi C, Casara D. Distribution of human recombinant interferon-2 in rat plasma, liver and experimental liver metastases. Mol Biother 1990; 2: 233
21. Quesada J, Evans L, Saks S, Gutterman J. Recombinant interferon alpha and gamma in combinations as treatment for metastatic renal cell carcinoma. J Bio Resp Modif 1988; 7: 234
22. Kurzrock R, Rosenblum M, Sherwin S. Pharmacokinetics, single dose tolerance and biological activity of recombinant gamma interferon in cancer patients. Cancer Res 1985; 45: 2866
23. FitzGerald D, Willingham M, Cardarelli C, Hamada H, Tsuruo T, Gottesman M, Pastan I. A monoclonal antibody-pseudomanas toxin conjugate that specifically kills multidrug-resistant cells. PNAS 1987; 84: 4288
24. Harven E, Fradet Y, Connolly J, Hana W, He S, Wang Y, Choi B, McGroarty R, Bootsma G, Tilup A, Christensen H. Antibody drug carrier for immunotherapy of superficial bladder cancer. Ultra-structural Studies. Cancer Res 1992; 52: 3131
25. Schmidberger H, Buchsbaum D, Blazar B, Everson P, Vallera D. Radiotherapy in mice with Yttrium-90-labeled anti-Ly 1 monoclonal antibody: Therapy of the T cell lymphoma EL4. Cancer Res 1991; 51: 1883
26. Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller L, Hinkle G, Siler K. Therapeutic advantage of high affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52: 1067
27. Hoogenboom H, Volckaert G, Raus J. Construction and expression of antibody-tumor necrosis factor fusion protein. Mol Immunol 1991; 28: 1027
28. Gillies S, Reilly E, Lo K, Reisfeld R. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. PNAS 1992; 89: 1428
29. Thor A, Ohuchi N, Szpak C, Johnston W, Schlom J. Distribution of the oncofetal antigen, tumor-associated glycoprotein-72 denned by the monoclonal antibody B72.3. Cancer Res 1986; 46: 3118
30. Xiang J, Moyana T, Kalra J, Hamilton T, Qi Y. Construction and characterization of a high affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol Biother 1992; 4: 174
31. Boyd M, Xiang J. Molecular cloning and expression of functionalcDNA genes of a mouse/human chimeric antibody rcM4. Tumori 1994; 80: 473
32. Harlow E, Lane D. Antibodies. A Laboratory Manual. Cold Spring Harbor: Cold Spring Laboratory Press, 1988
33. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies to the tumor-associated O-linked sialosyl 2.6a-N-Ace tyl-galactosaminyl (Sialosyl-Tn) epitope. Cancer Res 1988; 48: 2214
34. Hand P, Calvo B, Milenic D, Yokota T, Finch M, Snoy P, Garmestani K, Gansow O, Schlom J, Kashmiri S. Comparative biological properties of a recombinant chimeric anti-carcinoma MAb and a recombinant aglycosylated variant. Cancer Immunol Immunother 1992; 35: 165
35. Xiang J, Roder J, Hozumi N. Production of murine VThuman Crl chimeric anti-TAG72 antibody using V region cDNA amplified by PCR. Mol Immunol 1990; 27: 809
36. Xiang J. Genetic engineering of anticolorectal carcinoma FV molecule in myeloma cells. Mol Biother 1992; 4: 70
37. Xiang J, Kimura A. Isolation of metastatic B16 melanoma variants using anti-Met72 monoclonal antibodies and flow cytometry. Clin Expl Metastasis 1987; 5: 35
38. Xiang J, Moyana T, Chen Z, Han W, Ping T, Li E. Production and characterization of a tumor-specific monoclonal antibody ACT 19 recognizing an epitope distintive from sialosyl-Tn on the TAG72 antigen. Tumori 1993; 79: 58
39. Fearon E, Pardoll D, Itaya T, Golumbek P, Levitsky H, Simons J, Karasuyama H, Vogeistein B, Frost P. Interleukine-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397
40. Alkan S, Miescher S, Braun D, Hochkeppel H. Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies. J Interferon Res 1984; 4: 355
41. Alkan S, Towbin H, Hochkeppel H. Enhanced antiproliferative action of interferon targeted by bispecific monoclonal antibodies. J Interferon Res 1988; 8: 25
42. Brown B, Drzynski C, Dearbrorn C, Hadjlan R, Liberatore F, Haber S. Conjugation of metallothionein to a murine-monoclonal antibody. Anal Biochem 1988; 172: 22
43. Canevari S, Menard S, Mezzanzanica D. Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T cells. Int J Cancer 1988; 2: 18
44. Schnee J, Runge M, Matsueda G, Hudson N, Seidman J, Haber E, Quertermous T. Construction and expression of a recombinant antibody-targeted plasminogen activator. PNAS 1987; 84: 6904
45. Casadei J, Powell M, Kenten J. Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector. PNAS 1990; 87: 2047
46. Shin S, Morrison S. Expression and characterization of an antibody binding specificity joined to insulin-like growth factor I: potential application for cellular targeting. PNAS 1990; 87: 5322
47. Schneider W, Wensel T, Stryer L, Oi V. Genetically engineered immunoglobulins reveal structural features controlling segment flexibility. PNAS 1988; 85: 2509
48. Sabzevari H, Gillies S, Muller B, Pancookk J, Reisfeld R. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. PNAS 1994; 91: 9626